Open-label trial of Stealth liposomal doxorubicin (D-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (AIDS-KS) (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Open-label trial of Stealth liposomal doxorubicin (D-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (AIDS-KS) (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 13:A24 1994. Unique Identifier : AIDSLINE ICDB/94600021
Thommes J; Northfelt D; Rios A; Krown S; Leff R; Dosik G; Aboulafia D; Henry D; Pacific Oaks Medical Group, Beverly Hills, CA

Abstract: Forty-eight patients (pts) with AIDS-KS refractory to or intolerant of conventional systemic chemotherapy were evaluated for response to D-SL. D-SL 20 mg/m2 was administered every 3 wk (with cycle length modified depending on adverse events and response) for up to 10 cycles. KS lesions were evaluated according to ACTG criteria prior to trial entry, prior to and at the end of every cycle, and at 4 weeks following the end of the last cycle. Pts with partial response (PR) were followed every 2 months to determine response duration. The mean CD4 count of the study population was less than 50/mm3. Results are shown in a table. Mean cycle number at BR was approx 2.7 and the mean duration of PR was approx 83 days. D-SL was well tolerated. The majority of adverse events reported were mild or moderate in severity. Conclusions: (1) D-SL can produce PRs in up to two thirds of pts with AIDS-KS refractory to conventional chemotherapy; (2) PRs may be prolonged; (3) BRs are generally produced within the first several treatment cycles; (4) D-SL is generally well-tolerated with acceptable toxicity.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Doxorubicin/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Drug Administration Schedule Drug Carriers Follow-Up Studies Human Liposomes Sarcoma, Kaposi's/*DRUG THERAPY Skin Neoplasms/*DRUG THERAPY ABSTRACT CLINICAL TRIAL
940830
M9480782

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .